Canadian cell‑therapy hub CCRM and quantum computing company IonQ announced a strategic collaboration and an initial IonQ investment to explore quantum applications for advanced therapies and biomanufacturing. The partnership will identify use cases where quantum computing, AI and high‑performance analytics could transform therapeutic discovery, development and manufacturing costs. CCRM said the collaboration will leverage its global academic and industry network and OmniaBio’s CDMO relationships to scale quantum‑driven projects, with an eye toward reducing analytic bottlenecks in gene and cell therapy development. IonQ framed the effort as an opportunity to translate quantum advantage into biomedical workflows. This move signals growing interest in combining quantum computing with biotech R&D to tackle high‑dimensional optimization problems; early pilots will need to demonstrate concrete gains before broad adoption in regulated manufacturing and clinical settings.